平阳霉素治疗颈部大囊型淋巴管畸形的临床疗效观察  

Intralesional pingyangmycin injection in the management of macrocystic lymphatic malformations in cervical region

作　　者：雷博程[1] 高小波[1] 刘征宇[1] 魏景健[1] 薛雷[1] 王绪凯[1] 

机构地区：[1]中国医科大学口腔医学院,辽宁省口腔医学研究所口腔颌面外科,辽宁沈阳110002

出　　处：《上海口腔医学》2013年第2期233-236,共4页Shanghai Journal of Stomatology

摘　　要：目的:探讨平阳霉素治疗颈部大囊型淋巴管畸形的疗效。方法:采用平阳霉素注射治疗36例单侧颈部大囊型淋巴管畸形患者。注射前均将病变内囊液吸出,再注射药物。病变范围较大时,采用分象限分次注射。用药量及治疗周期依病变大小及年龄而定。随访时间为1～2 a。结果:总有效率为100%,治愈率为94.4%(34/36)。无肺纤维化及严重不良发应发生。结论:平阳霉素局部注射可作为颈部大囊型淋巴管畸形的首选治疗方法。PURPOSE： To investigate the therapeutic effects of pingyangmycin injection as a primary therapy of macrocystic lymphatic malformations in cervical region. METHODS： Thirty-six patients with macrocystic lymphatic malformations in cervical region underwent the therapy of pingyangmycin injection between 2009 and 2012 at School of Stomatology, China Medical University. Among them, 16 patients had unilateral submandibular lesions, 20 patients had lesions in anterior cervical regions. The age of patients was from 6 months to 25 yeas old. The concentration of the drug was 1.6 mg/mL with an addition of lidocaine. The dose and cycle of treatment were dependent on the lesions＇ size and patients＇ age. The follow-up period was 12 months to 2 years after the last treatment. RESULTS： The total effective rate was 100%, and the curative rate was 94.4%. No serious complications were encountered. CONCLUSIONS： Intralesional Injection of pingyangmycin provides a safe and effective treatment for macrocystic lymphatic malformations in cervical region as a primary treatment.

关 键 词：平阳霉素 颈部 大囊型淋巴管畸形 

分 类 号：R782[医药卫生—口腔医学]